Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 791 Cr.
- Current Price ₹ 671
- High / Low ₹ 1,385 / 636
- Stock P/E 40.0
- Book Value ₹ 205
- Dividend Yield 0.15 %
- ROCE 13.3 %
- ROE 9.98 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 89.4% CAGR over last 5 years
Cons
- Working capital days have increased from 103 days to 177 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 12 | 18 | 25 | 45 | 64 | 79 | |
| 12 | 18 | 21 | 34 | 43 | 53 | |
| Operating Profit | 0 | 1 | 4 | 11 | 21 | 26 |
| OPM % | 3% | 4% | 17% | 23% | 33% | 33% |
| 1 | 1 | 1 | 2 | 3 | 3 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 |
| Profit before tax | 1 | 1 | 5 | 11 | 22 | 27 |
| Tax % | 27% | 25% | 26% | 26% | 26% | 25% |
| 1 | 1 | 3 | 8 | 17 | 20 | |
| EPS in Rs | 4.29 | 9.66 | 14.33 | 16.86 | ||
| Dividend Payout % | 0% | 0% | 0% | 3% | 5% | 4% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 46% |
| 3 Years: | 47% |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 89% |
| 3 Years: | 79% |
| TTM: | 19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 15% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 1 | 1 | 1 | 6 |
| Reserves | 2 | 3 | 6 | 18 | 152 | 236 |
| 0 | 0 | 0 | 8 | 4 | 4 | |
| 3 | 8 | 9 | 8 | 26 | 34 | |
| Total Liabilities | 5 | 11 | 16 | 35 | 183 | 280 |
| 0 | 0 | 0 | 3 | 5 | 7 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 3 | 21 | 127 | 209 |
| 5 | 11 | 12 | 11 | 51 | 64 | |
| Total Assets | 5 | 11 | 16 | 35 | 183 | 280 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 1 | -0 | 5 | 5 | 6 | 16 | |
| -1 | -0 | -5 | -15 | -47 | -12 | |
| 0 | -0 | -0 | 12 | 42 | -1 | |
| Net Cash Flow | 1 | -0 | 0 | 2 | 1 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 50 | 71 | 43 | 39 | 83 | 72 |
| Inventory Days | 23 | 36 | 47 | 5 | 25 | 22 |
| Days Payable | 68 | 164 | 139 | 60 | 108 | 53 |
| Cash Conversion Cycle | 5 | -56 | -48 | -16 | 0 | 42 |
| Working Capital Days | 19 | -20 | -39 | 1 | 132 | 177 |
| ROCE % | 46% | 92% | 69% | 25% | 13% |
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
9 October 2025 - 58,92,000 bonus shares allotted (1:1) on July 7, 2025; listing July 8; new subsidiary; MD and WTD reappointed.
-
Updates
8 October 2025 - RTA MUFG Intime email changed to investor.helpdesk@in.mpms.mufg.com; service requests via provided web portal.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
8 October 2025 - Remus Pharma informs NSE exemption from Reg 27(2) under Reg15(2)(b) due to SME Emerge listing.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
8 October 2025 - Certificate under Regulation 74(5) for quarter ended 30 Sep 2025 confirming dematerialisation by MUFG Intime.
-
Trading Window
26 September 2025 - Trading window closed Oct 1, 2025 until 48 hours after unaudited results for half-year ending Sep 30, 2025.
Annual reports
Concalls
-
Aug 2025TranscriptNotesPPT
-
May 2025Transcript PPT
-
Nov 2024Transcript PPT REC
Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing